Cite
HARVARD Citation
Yellin, M. et al. (n.d.). 406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. Journal for immunotherapy of cancer. p. A431. [Online].